TP53 and endometrial cancer: A retrospective molecular analysis of the PORTEC-3 trial for high-risk endometrial cancer confirmed that women with p53-abnormal endometrial cancer had significantly improved recurrence-free survival when platinum-based chemotherapy was used alongside radiation, compared with radiation alone (67).